AbbVie to Acquire Aliada Therapeutics for ~$1.4B
Shots:
- AbbVie has agreed to acquire Aliada Therapeutics, bolstering its focus on Alzheimer's disease and neuroscience portfolio
- As per the agreement, AbbVie will buy all the outstanding shares of Aliada for $1.4B in cash, with the deal anticipated to close in Q4’24, pending regulatory and customary approvals
- The acquisition adds Aliada's lead asset, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in P-I trials for AD, and its Modular Delivery (MODEL) platform, enabling precision CNS drug delivery using BBB-crossing technology targeting TfR and CD98 receptors in brain endothelial cells to AbbVie’s portfolio
Ref: AbbVie | Image: Aliada Therapeutics
Related News:- AbbVie’s Elahere (Mirvetuximab Soravtansine) Receives the EC’s Approval to Treat Platinum-Resistant Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
